Table 3.
Overview of main pharmacokinetic properties of NOACs.
| Dabigatran etexilate | Rivaroxaban | Apixaban | |
|---|---|---|---|
| Plasma peak (hours) | 1.5–3.0 | 2.0–4.0 | 3.0-4.0 |
|
| |||
| Elimination half-life (hours) | 11–14: healthy volunteers 18–24: significantly impaired renal function |
5–9: healthy volunteers 11–13: elderly |
8–15: healthy volunteers |
|
| |||
| Protein binding (%) | 35% | >90% | 87% |
|
| |||
| Elimination (%) | 80% active renal 20% faecal |
33% non-active renal 66% metabolized: (metabolism: 50% renal and other half by hepatobiliary route) |
Multiples pathways: 25%–29% renal 56% by faecal route |
|
| |||
| Bioavailability | 3–7% PH sensitive |
80–100% 10 mg 66%: 15–20 mg under fasting conditions |
±50% |